Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 80 entries
Sorted by: Best Match Show Resources per page
Dyslipidemia in Pregnancy.

Endocrinology and metabolism clinics of North America

Wild R, Weedin EA, Wilson D.
PMID: 26892997
Endocrinol Metab Clin North Am. 2016 Mar;45(1):55-63. doi: 10.1016/j.ecl.2015.09.004.

"Recent studies have revealed evidence that poorly controlled cholesterol, triglycerides, and their metabolites during pregnancy may be associated with cardiometabolic dysfunction and have significant detrimental fetal and maternal vascular consequences. Cardiometabolic dysfunction during pregnancy may not only contribute to...

Cite
Wild R, Weedin EA, Wilson D. Dyslipidemia in Pregnancy. Endocrinol Metab Clin North Am. 2016;45(1):55-63doi: 10.1016/j.ecl.2015.09.004.
Wild, R., Weedin, E. A., & Wilson, D. (2016). Dyslipidemia in Pregnancy. Endocrinology and metabolism clinics of North America, 45(1), 55-63. https://doi.org/10.1016/j.ecl.2015.09.004
Wild, Robert, et al. "Dyslipidemia in Pregnancy." Endocrinology and metabolism clinics of North America vol. 45,1 (2016): 55-63. doi: https://doi.org/10.1016/j.ecl.2015.09.004
Wild R, Weedin EA, Wilson D. Dyslipidemia in Pregnancy. Endocrinol Metab Clin North Am. 2016 Mar;45(1):55-63. doi: 10.1016/j.ecl.2015.09.004. PMID: 26892997.
Copy Download .nbib Format: NLM
Women's Health Considerations for Lipid Management.

Endocrinology and metabolism clinics of North America

Wild R, Weedin EA, Gill EA.
PMID: 26892998
Endocrinol Metab Clin North Am. 2016 Mar;45(1):65-85. doi: 10.1016/j.ecl.2015.09.005.

Understanding opportunities to reduce dyslipidemia before, during, and after pregnancy has major implications for cardiovascular disease risk prevention for the entire population. The best time to screen for dyslipidemia is before pregnancy or in the early antenatal period. The...

Cite
Wild R, Weedin EA, Gill EA. Women's Health Considerations for Lipid Management. Endocrinol Metab Clin North Am. 2016;45(1):65-85doi: 10.1016/j.ecl.2015.09.005.
Wild, R., Weedin, E. A., & Gill, E. A. (2016). Women's Health Considerations for Lipid Management. Endocrinology and metabolism clinics of North America, 45(1), 65-85. https://doi.org/10.1016/j.ecl.2015.09.005
Wild, Robert, et al. "Women's Health Considerations for Lipid Management." Endocrinology and metabolism clinics of North America vol. 45,1 (2016): 65-85. doi: https://doi.org/10.1016/j.ecl.2015.09.005
Wild R, Weedin EA, Gill EA. Women's Health Considerations for Lipid Management. Endocrinol Metab Clin North Am. 2016 Mar;45(1):65-85. doi: 10.1016/j.ecl.2015.09.005. PMID: 26892998.
Copy Download .nbib Format: NLM
Metabolic syndrome.

Endocrinology and metabolism clinics of North America

Samson SL, Garber AJ.
PMID: 24582089
Endocrinol Metab Clin North Am. 2014 Mar;43(1):1-23. doi: 10.1016/j.ecl.2013.09.009.

Metabolic syndrome is not a disease per se, but is a term that highlights traits that may have an increased risk of disease, approximately 2-fold for cardiovascular disease and 5-fold or more for type 2 diabetes mellitus. Obesity and...

Cite
Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am. 2014;43(1):1-23doi: 10.1016/j.ecl.2013.09.009.
Samson, S. L., & Garber, A. J. (2014). Metabolic syndrome. Endocrinology and metabolism clinics of North America, 43(1), 1-23. https://doi.org/10.1016/j.ecl.2013.09.009
Samson, Susan L, and Garber, Alan J. "Metabolic syndrome." Endocrinology and metabolism clinics of North America vol. 43,1 (2014): 1-23. doi: https://doi.org/10.1016/j.ecl.2013.09.009
Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am. 2014 Mar;43(1):1-23. doi: 10.1016/j.ecl.2013.09.009. PMID: 24582089.
Copy Download .nbib Format: NLM
A Population-Based Approach to Diabetes and Prediabetes.

Endocrinology and metabolism clinics of North America

Ioachimescu AG.
PMID: 34399963
Endocrinol Metab Clin North Am. 2021 Sep;50(3):xv-xvi. doi: 10.1016/j.ecl.2021.06.002.

No abstract available.

Cite
Ioachimescu AG. A Population-Based Approach to Diabetes and Prediabetes. Endocrinol Metab Clin North Am. 2021;50(3):xv-xvidoi: 10.1016/j.ecl.2021.06.002.
Ioachimescu, A. G. (2021). A Population-Based Approach to Diabetes and Prediabetes. Endocrinology and metabolism clinics of North America, 50(3), xv-xvi. https://doi.org/10.1016/j.ecl.2021.06.002
Ioachimescu, Adriana G. "A Population-Based Approach to Diabetes and Prediabetes." Endocrinology and metabolism clinics of North America vol. 50,3 (2021): xv-xvi. doi: https://doi.org/10.1016/j.ecl.2021.06.002
Ioachimescu AG. A Population-Based Approach to Diabetes and Prediabetes. Endocrinol Metab Clin North Am. 2021 Sep;50(3):xv-xvi. doi: 10.1016/j.ecl.2021.06.002. PMID: 34399963.
Copy Download .nbib Format: NLM
An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective.

Endocrinology and metabolism clinics of North America

Tinajero MG, Malik VS.
PMID: 34399949
Endocrinol Metab Clin North Am. 2021 Sep;50(3):337-355. doi: 10.1016/j.ecl.2021.05.013.

Type 2 diabetes (T2D) is a public health burden associated with immense health care and societal costs, early death, and morbidity. Largely because of epidemiologic changes, including nutrition transitions, urbanization, and sedentary lifestyles, T2D is increasing in every region...

Cite
Tinajero MG, Malik VS. An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Endocrinol Metab Clin North Am. 2021;50(3):337-355doi: 10.1016/j.ecl.2021.05.013.
Tinajero, M. G., & Malik, V. S. (2021). An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Endocrinology and metabolism clinics of North America, 50(3), 337-355. https://doi.org/10.1016/j.ecl.2021.05.013
Tinajero, Maria G, and Malik, Vasanti S. "An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective." Endocrinology and metabolism clinics of North America vol. 50,3 (2021): 337-355. doi: https://doi.org/10.1016/j.ecl.2021.05.013
Tinajero MG, Malik VS. An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Endocrinol Metab Clin North Am. 2021 Sep;50(3):337-355. doi: 10.1016/j.ecl.2021.05.013. PMID: 34399949.
Copy Download .nbib Format: NLM
Population-Level Approaches to Preventing Type 2 Diabetes Globally.

Endocrinology and metabolism clinics of North America

Siegel KR, Albright AL.
PMID: 34399953
Endocrinol Metab Clin North Am. 2021 Sep;50(3):401-414. doi: 10.1016/j.ecl.2021.05.010.

Type 2 diabetes (T2DM) is increasingly considered an epidemic rooted in modern society as much as in individual behavior. Addressing the T2DM burden thus involves a dual approach, simultaneously addressing high-risk individuals and whole populations. Within this context, this...

Cite
Siegel KR, Albright AL. Population-Level Approaches to Preventing Type 2 Diabetes Globally. Endocrinol Metab Clin North Am. 2021;50(3):401-414doi: 10.1016/j.ecl.2021.05.010.
Siegel, K. R., & Albright, A. L. (2021). Population-Level Approaches to Preventing Type 2 Diabetes Globally. Endocrinology and metabolism clinics of North America, 50(3), 401-414. https://doi.org/10.1016/j.ecl.2021.05.010
Siegel, Karen R, and Albright, Ann L. "Population-Level Approaches to Preventing Type 2 Diabetes Globally." Endocrinology and metabolism clinics of North America vol. 50,3 (2021): 401-414. doi: https://doi.org/10.1016/j.ecl.2021.05.010
Siegel KR, Albright AL. Population-Level Approaches to Preventing Type 2 Diabetes Globally. Endocrinol Metab Clin North Am. 2021 Sep;50(3):401-414. doi: 10.1016/j.ecl.2021.05.010. PMID: 34399953.
Copy Download .nbib Format: NLM
Ethnic Disparities in Diabetes.

Endocrinology and metabolism clinics of North America

Mikhail N, Wali S, Brown AF.
PMID: 34399957
Endocrinol Metab Clin North Am. 2021 Sep;50(3):475-490. doi: 10.1016/j.ecl.2021.05.006. Epub 2021 Jul 12.

Diabetes disproportionably affects minorities in the United States. Substantial disparities exist in diabetes incidence, glycemic control, complications, mortality, and management. The most important biologic contributors to diabetes disparities are obesity, insulin resistance, and inadequate glycemic control. Providers and health...

Cite
Mikhail N, Wali S, Brown AF. Ethnic Disparities in Diabetes. Endocrinol Metab Clin North Am. 2021;50(3):475-490doi: 10.1016/j.ecl.2021.05.006.
Mikhail, N., Wali, S., & Brown, A. F. (2021). Ethnic Disparities in Diabetes. Endocrinology and metabolism clinics of North America, 50(3), 475-490. https://doi.org/10.1016/j.ecl.2021.05.006
Mikhail, Nasser, et al. "Ethnic Disparities in Diabetes." Endocrinology and metabolism clinics of North America vol. 50,3 (2021): 475-490. doi: https://doi.org/10.1016/j.ecl.2021.05.006
Mikhail N, Wali S, Brown AF. Ethnic Disparities in Diabetes. Endocrinol Metab Clin North Am. 2021 Sep;50(3):475-490. doi: 10.1016/j.ecl.2021.05.006. Epub 2021 Jul 12. PMID: 34399957.
Copy Download .nbib Format: NLM
Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis.

Endocrinology and metabolism clinics of North America

Zeytinoglu M, Naaman SC, Dickens LT.
PMID: 34023039
Endocrinol Metab Clin North Am. 2021 Jun;50(2):205-222. doi: 10.1016/j.ecl.2021.03.004.

Denosumab (DMAB) is a potent antiresorptive treatment used for treatment of osteoporosis and low bone mineral density (BMD) in those at high risk for fracture. In postmenopausal women with osteoporosis, DMAB treatment for 10 years has been studied, with...

Cite
Zeytinoglu M, Naaman SC, Dickens LT. Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis. Endocrinol Metab Clin North Am. 2021;50(2):205-222doi: 10.1016/j.ecl.2021.03.004.
Zeytinoglu, M., Naaman, S. C., & Dickens, L. T. (2021). Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis. Endocrinology and metabolism clinics of North America, 50(2), 205-222. https://doi.org/10.1016/j.ecl.2021.03.004
Zeytinoglu, Meltem, et al. "Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis." Endocrinology and metabolism clinics of North America vol. 50,2 (2021): 205-222. doi: https://doi.org/10.1016/j.ecl.2021.03.004
Zeytinoglu M, Naaman SC, Dickens LT. Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis. Endocrinol Metab Clin North Am. 2021 Jun;50(2):205-222. doi: 10.1016/j.ecl.2021.03.004. PMID: 34023039.
Copy Download .nbib Format: NLM
Strategies for Physical Activity Interventions in the Treatment of Obesity.

Endocrinology and metabolism clinics of North America

Jakicic JM, Rogers RJ, Collins AM, Jackson R.
PMID: 32418591
Endocrinol Metab Clin North Am. 2020 Jun;49(2):289-301. doi: 10.1016/j.ecl.2020.02.004. Epub 2020 Apr 15.

Physical activity contributes to body weight regulation. At least 150 minutes per week of moderate-to-vigorous intensity physical activity may be needed. When not coupled with dietary restriction, physical activity contributes to an average weight loss of approximately 2 to...

Cite
Jakicic JM, Rogers RJ, Collins AM, et al. Strategies for Physical Activity Interventions in the Treatment of Obesity. Endocrinol Metab Clin North Am. 2020;49(2):289-301doi: 10.1016/j.ecl.2020.02.004.
Jakicic, J. M., Rogers, R. J., Collins, A. M., & Jackson, R. (2020). Strategies for Physical Activity Interventions in the Treatment of Obesity. Endocrinology and metabolism clinics of North America, 49(2), 289-301. https://doi.org/10.1016/j.ecl.2020.02.004
Jakicic, John M, et al. "Strategies for Physical Activity Interventions in the Treatment of Obesity." Endocrinology and metabolism clinics of North America vol. 49,2 (2020): 289-301. doi: https://doi.org/10.1016/j.ecl.2020.02.004
Jakicic JM, Rogers RJ, Collins AM, Jackson R. Strategies for Physical Activity Interventions in the Treatment of Obesity. Endocrinol Metab Clin North Am. 2020 Jun;49(2):289-301. doi: 10.1016/j.ecl.2020.02.004. Epub 2020 Apr 15. PMID: 32418591.
Copy Download .nbib Format: NLM
Obesity: A Closer Look.

Endocrinology and metabolism clinics of North America

Ioachimescu AG.
PMID: 32418595
Endocrinol Metab Clin North Am. 2020 Jun;49(2):xi-xii. doi: 10.1016/j.ecl.2020.04.001. Epub 2020 Apr 15.

No abstract available.

Cite
Ioachimescu AG. Obesity: A Closer Look. Endocrinol Metab Clin North Am. 2020;49(2):xi-xiidoi: 10.1016/j.ecl.2020.04.001.
Ioachimescu, A. G. (2020). Obesity: A Closer Look. Endocrinology and metabolism clinics of North America, 49(2), xi-xii. https://doi.org/10.1016/j.ecl.2020.04.001
Ioachimescu, Adriana G. "Obesity: A Closer Look." Endocrinology and metabolism clinics of North America vol. 49,2 (2020): xi-xii. doi: https://doi.org/10.1016/j.ecl.2020.04.001
Ioachimescu AG. Obesity: A Closer Look. Endocrinol Metab Clin North Am. 2020 Jun;49(2):xi-xii. doi: 10.1016/j.ecl.2020.04.001. Epub 2020 Apr 15. PMID: 32418595.
Copy Download .nbib Format: NLM
Hereditary Primary Hyperparathyroidism.

Endocrinology and metabolism clinics of North America

Newey PJ.
PMID: 34774240
Endocrinol Metab Clin North Am. 2021 Dec;50(4):663-681. doi: 10.1016/j.ecl.2021.08.003.

Primary hyperparathyroidism (PHPT) is a commonly encountered clinical problem and occurs as part of an inherited disorder in ∼10% of patients. Several features may alert the clinician to the possibility of a hereditary PHPT disorder (eg, young age of...

Cite
Newey PJ. Hereditary Primary Hyperparathyroidism. Endocrinol Metab Clin North Am. 2021;50(4):663-681doi: 10.1016/j.ecl.2021.08.003.
Newey, P. J. (2021). Hereditary Primary Hyperparathyroidism. Endocrinology and metabolism clinics of North America, 50(4), 663-681. https://doi.org/10.1016/j.ecl.2021.08.003
Newey, Paul J. "Hereditary Primary Hyperparathyroidism." Endocrinology and metabolism clinics of North America vol. 50,4 (2021): 663-681. doi: https://doi.org/10.1016/j.ecl.2021.08.003
Newey PJ. Hereditary Primary Hyperparathyroidism. Endocrinol Metab Clin North Am. 2021 Dec;50(4):663-681. doi: 10.1016/j.ecl.2021.08.003. PMID: 34774240.
Copy Download .nbib Format: NLM
Endocrine Disorders with Parathyroid Hormone-Independent Hypercalcemia.

Endocrinology and metabolism clinics of North America

Simonsen JK, Rejnmark L.
PMID: 34774242
Endocrinol Metab Clin North Am. 2021 Dec;50(4):711-720. doi: 10.1016/j.ecl.2021.07.002.

The most common causes of hypercalcemia are primary hyperparathyroidism and malignancy, constituting 80% to 90% of all cases. Although less common, several nonparathyroid endocrine disorders are associated with hypercalcemia. The most well described is hyperthyroidism, although the reported prevalence...

Cite
Simonsen JK, Rejnmark L. Endocrine Disorders with Parathyroid Hormone-Independent Hypercalcemia. Endocrinol Metab Clin North Am. 2021;50(4):711-720doi: 10.1016/j.ecl.2021.07.002.
Simonsen, J. K., & Rejnmark, L. (2021). Endocrine Disorders with Parathyroid Hormone-Independent Hypercalcemia. Endocrinology and metabolism clinics of North America, 50(4), 711-720. https://doi.org/10.1016/j.ecl.2021.07.002
Simonsen, Jo Krogsgaard, and Rejnmark, Lars. "Endocrine Disorders with Parathyroid Hormone-Independent Hypercalcemia." Endocrinology and metabolism clinics of North America vol. 50,4 (2021): 711-720. doi: https://doi.org/10.1016/j.ecl.2021.07.002
Simonsen JK, Rejnmark L. Endocrine Disorders with Parathyroid Hormone-Independent Hypercalcemia. Endocrinol Metab Clin North Am. 2021 Dec;50(4):711-720. doi: 10.1016/j.ecl.2021.07.002. PMID: 34774242.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 80 entries